Sequential Philadelphia-Positive Pre-B Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia With Distinct BCR::ABL1 Fusion Transcripts.
- 1School of Medicine, Arak University of Medical Sciences, Arak, Iran.
- 2Student Research Committee, Arak University of Medical Sciences, Arak, Iran.
Abstract
Background
The sequential emergence of chronic myeloid leukemia (CML) following Philadelphia-positive acute lymphoblastic leukemia (ALL) is exceedingly rare, and its biological basis remains uncertain.Case
We report a 15-year-old boy initially diagnosed at age 4 with Philadelphia-positive pre-B ALL expressing p190 BCR::ABL1. He achieved deep molecular remission following chemotherapy per the COG AALL0232-based high-risk B-ALL protocol plus imatinib. Approximately 5 years after his last documented follow-up, he re-presented with splenomegaly, leukocytosis, anemia, and thrombocytosis. Bone marrow findings supported chronic-phase CML, confirmed by detection of BCR::ABL1 p210 (b2a2 and b3a2) with no detectable p190. Responses to imatinib and dasatinib were suboptimal, and kinase-domain analysis identified a rare ABL1 c.1159T>A (p.Leu387Met) variant. He subsequently underwent matched-related allogeneic hematopoietic stem cell transplantation and remains BCR::ABL1-negative on nilotinib.Conclusion
This case expands the spectrum of sequential Philadelphia-positive leukemias by documenting p190-positive pre-B ALL followed by p210-positive chronic-phase CML, accompanied by detection of the rare L387M variant and suboptimal responses to imatinib and dasatinib. The biological relationship between the two Philadelphia-positive malignancies remains uncertain, with possible explanations including evolution from a shared Philadelphia-positive precursor, therapy-related leukemogenesis, or an independent second malignancy. This case provides unique insight into the biological complexity of sequential Philadelphia-positive leukemias and adds to the evolving literature regarding the clinical significance of the L387M variant in TKI response. The unsupervised TKI interruption underscores that any consideration of treatment discontinuation should occur only under specialist supervision with close molecular monitoring, while the discordance between the observed response and reported L387M sensitivity patterns warrants further investigation.
Related
- Evaluation of BCR::ABL1 Positivity in Peripheral Blood Neutrophils Enables the Diagnosis of De Novo Blast Phase Chronic Myeloid Leukemia with Additional Structural Abnormalities of the Philadelphia Chromosome
- Understanding and clinical approach to early T-cell precursor acute lymphoblastic leukemia
- B‐Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20‐Year‐Old Woman
- Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3
- Mothers' emotional and caregiving experiences during the first month after a child's acute lymphoblastic leukemia diagnosis: A qualitative study
BibTeX
@article{latifi2026sequential,
title = {{Sequential Philadelphia-Positive Pre-B Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia With Distinct BCR::ABL1 Fusion Transcripts.}},
author = {Atbin Latifi and Sina Yousefian},
journal = {Cancer reports (Hoboken, N.J.)},
year = {2026},
month = oct,
doi = {10.1002/cnr2.70694},
url = {https://europepmc.org/article/MED/42924531},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sequential Philadelphia-Positive Pre-B Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia With Distinct BCR::ABL1 Fusion Transcripts.
AU - Atbin Latifi
AU - Sina Yousefian
PY - 2026
DA - 2026/10/01
JO - Cancer reports (Hoboken, N.J.)
DO - 10.1002/cnr2.70694
UR - https://europepmc.org/article/MED/42924531
AB - Background The sequential emergence of chronic myeloid leukemia (CML) following Philadelphia-positive acute lymphoblastic leukemia (ALL) is exceedingly rare, and its biological basis remains uncertain.Case We report a 15-year-old boy initially diagnosed at age 4 with Philadelphia-positive pre-B ALL expressing p190 BCR::ABL1. He achieved deep molecular remission following chemotherapy per the COG AALL0232-based high-risk B-ALL protocol plus imatinib. Approximately 5 years after his last documented follow-up, he re-presented with splenomegaly, leukocytosis, anemia, and thrombocytosis. Bone marrow findings supported chronic-phase CML, confirmed by detection of BCR::ABL1 p210 (b2a2 and b3a2) with no detectable p190. Responses to imatinib and dasatinib were suboptimal, and kinase-domain analysis identified a rare ABL1 c.1159T>A (p.Leu387Met) variant. He subsequently underwent matched-related allogeneic hematopoietic stem cell transplantation and remains BCR::ABL1-negative on nilotinib.Conclusion This case expands the spectrum of sequential Philadelphia-positive leukemias by documenting p190-positive pre-B ALL followed by p210-positive chronic-phase CML, accompanied by detection of the rare L387M variant and suboptimal responses to imatinib and dasatinib. The biological relationship between the two Philadelphia-positive malignancies remains uncertain, with possible explanations including evolution from a shared Philadelphia-positive precursor, therapy-related leukemogenesis, or an independent second malignancy. This case provides unique insight into the biological complexity of sequential Philadelphia-positive leukemias and adds to the evolving literature regarding the clinical significance of the L387M variant in TKI response. The unsupervised TKI interruption underscores that any consideration of treatment discontinuation should occur only under specialist supervision with close molecular monitoring, while the discordance between the observed response and reported L387M sensitivity patterns warrants further investigation.
SN - 2573-8348
ER -